Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Short

Showing results (531-540 of 659) with videos related to

Pageof 66
Sort By:
Nature Communications|October 13, 2019
Contribution of retrotransposition to developmental disordersEugene J Gardner, Elena Prigmore, Giuseppe Gallone, et al.
JNCI Cancer Spectrum|June 27, 2025
Risk of early death after acute leukemia diagnosis among adolescents and young adultsAmy M Berkman, Clark R Andersen, Vidya Puthenpura, et al.
Physiology & Behavior|June 18, 2025
Gut microbiome is associated with insula structure in neonatesMichelle Graf, Nicolas Murgueitio, Margaret A Sheridan, et al.
American Journal of Hematology|January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationPatrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Leukemia & Lymphoma|June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignanciesGeorgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
Pageof 66

Showing results (531-540 of 659) with videos related to

Sort By:
Pageof 66
Nature Communications|October 13, 2019
Contribution of retrotransposition to developmental disordersEugene J Gardner, Elena Prigmore, Giuseppe Gallone, et al.
JNCI Cancer Spectrum|June 27, 2025
Risk of early death after acute leukemia diagnosis among adolescents and young adultsAmy M Berkman, Clark R Andersen, Vidya Puthenpura, et al.
Physiology & Behavior|June 18, 2025
Gut microbiome is associated with insula structure in neonatesMichelle Graf, Nicolas Murgueitio, Margaret A Sheridan, et al.
American Journal of Hematology|January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationPatrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Leukemia & Lymphoma|June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignanciesGeorgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
Pageof 66